🇺🇸 FDA
Patent

US 8680131

Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

granted A61KA61K31/415A61K45/06

Quick answer

US patent 8680131 (Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers) held by Jenrin Discovery, LLC expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Jenrin Discovery, LLC
Grant date
Tue Mar 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/415, A61K45/06, A61P, A61P1/00